Recent advances in the treatment of tobacco dependence

First, we examine the role of the endocannabinoid system (ECS) in the development of nicotine dependence and highlight the development of rimonabant, the first selective antagonist of the cannabinoid type 1 (CB-1) receptor. Second, we explore how heterogeneity among various subtypes of nicotinic receptors might be exploited to develop more specific agents acting at these receptors such as varenicline-a partial agonist at the α4β2 nicotinic receptor. Finally, we examine how selective inhibitors of monoamine oxidase (MAO) such as selegiline might be used as adjunctive medications for the treatment of tobacco dependence.